Skip to main content
Premium Trial:

Request an Annual Quote

Kreatech, Sigma-Aldrich, Gene Logic


Dutch biotech company Kreatech has launched labeling kits for the DNA microarray market using GE Healthcare’s Universal System Linkage technology. The company said that its first commercially available kits are optimized for labeling of amplified RNA for gene-expression analysis and for labeling of genomic DNA for microarray based comparative genomic hybridization.

Sigma-Aldrich this week launched its Panorama Human p53 Protein Functional Microarray. The p53 protein array was developed by Procognia, and the companies claim that the technology ensures that “the protein is correctly folded and confers full functionality.” The array also includes wild human genome variants, and the companies said that additional arrays will follow.

Gene Logic this week launched ToxShield Suite 1.0, a Web-enabled software platform for assessing and ranking drug compounds based on potential toxicities in humans. Gene Logic said that the software will be used by toxicologists and drug safety scientists at global pharmaceutical companies to aid in their compound development decision-making processes and will be useful in developing screening assays.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.